| Catalog No. | HV721016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | V-set domain-containing T-cell activation inhibitor 1, B7h.5, B7 homolog 4, B7-H4, T-cell costimulatory molecule B7x, B7H4, VTCN1, Protein B7S1, Immune costimulatory protein B7-H4 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | Q7Z7D3 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | FPA-150, FPA150, 2254029-91-7 |
|---|
| Background | HY-P990996 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
• Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance., PMID:38968937
• B7-H4, a promising target for immunotherapy., PMID:31733822
• A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression., PMID:37882675
• Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers., PMID:32938586
• V-set domain containing T-cell activation inhibitor-1 (VTCN1): A potential target for the treatment of autoimmune diseases., PMID:36095871
• Palmitoylation prevents B7-H4 lysosomal degradation sustaining tumor immune evasion., PMID:40341398
• Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)., PMID:30850021
• The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial., PMID:31677920
• B7-H4 reduces the infiltration of CD8+T cells and induces their anti-tumor dysfunction in gliomas., PMID:38796932
• Potential targeting of B7-H4 for the treatment of cancer., PMID:28258701
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
